StackAI
StackAI is an enterprise AI automation platform that allows organizations to build end-to-end internal tools and processes with AI agents. It ensures every workflow is secure, compliant, and governed, so teams can automate complex processes without heavy engineering.
With a visual workflow builder and multi-agent orchestration, StackAI enables full automation from knowledge retrieval to approvals and reporting. Enterprise data sources like SharePoint, Confluence, Notion, Google Drive, and internal databases can be connected with versioning, citations, and access controls to protect sensitive information.
AI agents can be deployed as chat assistants, advanced forms, or APIs integrated into Slack, Teams, Salesforce, HubSpot, ServiceNow, or custom apps.
Security is built in with SSO (Okta, Azure AD, Google), RBAC, audit logs, PII masking, and data residency. Analytics and cost governance let teams track performance, while evaluations and guardrails ensure reliability before production.
StackAI also offers model flexibility, routing tasks across OpenAI, Anthropic, Google, or local LLMs with fine-grained controls for accuracy.
A template library accelerates adoption with ready-to-use workflows like Contract Analyzer, Support Desk AI Assistant, RFP Response Builder, and Investment Memo Generator.
By consolidating fragmented processes into secure, AI-powered workflows, StackAI reduces manual work, speeds decision-making, and empowers teams to build trusted automation at scale.
Learn more
SciSure
SciSure is reshaping the future of laboratories worldwide with forward-thinking digital solutions. Our Digital Lab Platform (DLP) unites key tools such as Electronic Lab Notebook (ELN), Laboratory Information Management Systems (LIMS), and advanced technologies like AI and machine learning. Built for seamless compatibility with your lab's hardware and software, the platform enhances flexibility, security, and efficiency. By consolidating and optimizing your research and development workflows within a secure and compliant environment, we help researchers dedicate more time to innovation. Our expert team is committed to supporting you at every stage of your digital lab transformation.
Learn more
Genedata Biologics
Genedata Biologics® enhances the development of biotherapeutics, including bispecifics, ADCs, TCRs, CAR-Ts, and AAVs, providing a comprehensive solution for the industry. Recognized as the leading platform in the field, it seamlessly unifies all discovery workflows, allowing researchers to prioritize genuine innovation. By utilizing a pioneering platform that was purposefully created to digitalize the biotherapeutic discovery process, research can be accelerated significantly. The platform simplifies intricate R&D tasks by facilitating the design, tracking, testing, and evaluation of novel biotherapeutic drugs. It is compatible with various formats, such as antibodies, bi- or multi-specifics, ADCs, innovative scaffolds, and therapeutic proteins, as well as engineered therapeutic cell lines like TCRs and CAR-T cells. Functioning as a comprehensive end-to-end data backbone, Genedata Biologics connects all R&D processes, including library design, immunization, selection and panning, molecular biology, screening, protein engineering, expression, purification, and protein analytics, ultimately leading to thorough assessments of candidate developability and manufacturability. This holistic integration ensures that researchers can make informed decisions and push the boundaries of biotherapeutic innovation effectively.
Learn more
Atomwise
Our innovative AI engine is revolutionizing the drug discovery process, enabling the creation of superior medications at an accelerated pace. The breakthroughs we achieve contribute to the development of medicines more efficiently and effectively. Our portfolio of AI-driven discoveries encompasses entirely owned and collaboratively developed pipeline assets, supported by leading investors in the industry. Atomwise has engineered a cutting-edge machine-learning discovery platform that merges the capabilities of convolutional neural networks with extensive chemical libraries to identify new small-molecule treatments. The key to transforming drug discovery through AI lies in our talented team. We are committed to enhancing our AI platform and leveraging it to revolutionize the discovery of small molecule drugs. It is essential that we confront the most daunting and seemingly insurmountable targets, streamlining the entire drug discovery process to provide developers with increased opportunities for success. Enhanced computational efficiency allows us to screen trillions of compounds virtually, significantly boosting the chances of finding viable solutions. Our impressive model accuracy has successfully addressed the persistent issue of false positives, underscoring the reliability of our approach. Ultimately, our dedication to innovation and excellence sets us apart in the quest for breakthrough therapies.
Learn more